公开(公告)号：WO2014011891A1

公开(公告)日：2014-01-16

申请号：PCT/US2013/050094

申请日：2013-07-11

Applicant: OSIRIS THERAPEUTICS, INC.

Inventor： YOO, Dana Sue ,  KUANG, Jin-Qiang ,  PADEN, Jaime ,  MAXSON, Scott A. ,  DANILKOVITCH, Alla ,  LOPEZ, Erasmo ,  TOM, Samson

IPC: A61F2/28

CPC classification number: A61L27/3612 ,  A61K35/32 ,  A61K38/014 ,  A61L27/24 ,  A61L27/3608 ,  A61L27/3654 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/50 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/414 ,  A61L2300/64 ,  A61L2430/06

Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract translation: 本发明提供了有价软骨产品和生产门软骨产品的方法。 任选地，软骨产品的尺寸，开口和消化以提供柔性软骨产品。 任选地，软骨产品包括活的软骨细胞，生物活性因子如软骨形成因子和II型胶原蛋白。 任选地，软骨产品是非免疫原性的。

公开(公告)号：WO2013002553A2

公开(公告)日：2013-01-03

申请号：PCT/KR2012/005085

申请日：2012-06-27

Applicant: 김지형

Inventor： 김지형

CPC classification number: C12N5/0655 ,  A61F2/3872 ,  A61K35/32 ,  A61L27/3612 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/3895 ,  A61L2430/06 ,  C12N2509/00

Abstract: 본 발명은 이식을 위한 효과적인 연골세포 증식(확장) 방법 및 이를 이용한이식용 조성물에 관한 것으로, 보다 구체적으로는 콜라게네이즈를 처리한 연골절편을 신선 동결된 반월상 연골내 삽입하여 이식하거나 배양하여 이식하면 중심부 및 주변부에서 효과적으로 연골세포가 증식하므로, 연골 이식을 요하는 연골 질환 치료에 매우 유용하다.

Abstract translation: 本发明涉及一种用于有效增殖（扩大）用于移植的软骨细胞的方法，以及使用该方法的用于移植的组合物。 更具体地说，当用胶原酶处理的软骨片段可以插入并移植到新鲜冷冻的半月板软骨中时，或者当可以培养并随后移植时，软骨细胞在半月板软骨的中心和周围有效地增殖。 因此，本发明的方法和组合物在治疗需要软骨移植的软骨疾病方面可能是非常有价值的。

公开(公告)号：WO2012103881A2

公开(公告)日：2012-08-09

申请号：PCT/DE2012000415

申请日：2012-04-17

Applicant: HILDEBRANDT BERNHARD

Inventor： HILDEBRANDT BERNHARD

CPC classification number: A61F2/30756 ,  A61F2/30749 ,  A61F2/3094 ,  A61F2/34 ,  A61F2/3603 ,  A61F2/4609 ,  A61F2002/30448 ,  A61F2002/30762 ,  A61F2002/30766 ,  A61F2002/30878 ,  A61F2002/3092 ,  A61F2002/30971 ,  A61F2002/3401 ,  A61F2002/4628 ,  A61F2002/4685 ,  A61F2002/485 ,  A61F2002/487 ,  A61F2310/00011 ,  A61F2310/00293 ,  A61F2310/00371 ,  A61F2310/00982 ,  A61L27/3612 ,  A61L27/3817 ,  A61L27/3821 ,  A61L27/3843 ,  A61L27/3891 ,  A61L2430/24

Abstract: The present invention overcomes the problems of conventional mechanical endoprostheses and the drawbacks of current methods of cartilage replacement by making provisions for the production of a complete biological joint replacement. In order to produce a biological joint replacement having hyaline cartilage, which can cope with heavy loads, devices are used for the shaping, the promotion of diffusion and in particular the compression of the joint replacement that is to be produced, i.e. a compression with alternating pressures and eventually a sliding movement of the walker on the surface of the joint replacement. The invention also relates to substances and methods for promoting the formation of hyaline cartilage tissue. The biological joint replacement is currently preferably suited for implantation in the shoulder and the hip, but can also be applied to other joints by using multi-dimensional milling techniques.

Abstract translation: 本发明通过提供生产完整生物关节置换绕过传统的机械假肢和的现有软骨替换方法的局限性的问题。 以产生具有透明软骨的可靠生物关节置换中，使用的设备，该形状的形成，促进扩散和特别是该产品的弯曲以提供关节置换，即 具有变化的压力和可能的关节置换的表面上滑动的助行器的移动的压缩。 还提供是促进透明软骨组织的形成材料和方法。 目前的生物关节置换优选用于肩部和臀部植入，但也适用于通过使用多维研磨技术接头等。

公开(公告)号：WO2012021490A1

公开(公告)日：2012-02-16

申请号：PCT/US2011/047041

申请日：2011-08-09

Applicant: LIFECELL CORPORATION ,  OWENS, Rick, T. ,  ELMO, Laura ,  LIU, Mike ,  MAO, Yong

Inventor： OWENS, Rick, T. ,  ELMO, Laura ,  LIU, Mike ,  MAO, Yong

IPC: A61L27/48 ,  A61L27/50

CPC classification number: A61L27/44 ,  A61L27/3608 ,  A61L27/3612 ,  A61L27/362 ,  A61L27/3683 ,  C08L67/04 ,  C08L5/08

Abstract: Methods, mixtures, and kits related to treating tissue are provided. The methods, mixtures, and kits can include an acellular tissue matrix, a polymer, and a solvent and may be capable of producing tissue scaffolds. The tissue scaffolds may be able to form a stable, three-dimensional shape in situ and elicit a limited immunologic or inflammatory response.

Abstract translation: 提供了与治疗组织相关的方法，混合物和试剂盒。 方法，混合物和试剂盒可以包括无细胞组织基质，聚合物和溶剂，并且可以能够产生组织支架。 组织支架可能能够原位形成稳定的三维形状，并引起有限的免疫学或炎症反应。

公开(公告)号：WO2010083051A9

公开(公告)日：2010-10-28

申请号：PCT/US2010000108

申请日：2010-01-14

Applicant: PROCHON BIOTECH LTD ,  MUSCULOSKELETAL TRANSPLANT ,  YAYON AVNER ,  TRUNCALE KATHERINE G ,  BARKAY-OLAMI HILLA ,  CALLAHAN ALEX B ,  GERTZMAN ARTHUR A ,  HUANG YEN-CHEN ,  JACOBS MORRIS L ,  MUNSON JOHN C ,  SEMLER ERIC J ,  SHIKHANOVICH ROMAN ,  STERN BARUCH ,  SUNWOO MOON HAE ,  TOMFORD WILLIAM W ,  YANNARIELLO-BROWN JUDITH I

Inventor： YAYON AVNER ,  TRUNCALE KATHERINE G ,  BARKAY-OLAMI HILLA ,  CALLAHAN ALEX B ,  GERTZMAN ARTHUR A ,  HUANG YEN-CHEN ,  JACOBS MORRIS L ,  MUNSON JOHN C ,  SEMLER ERIC J ,  SHIKHANOVICH ROMAN ,  STERN BARUCH ,  SUNWOO MOON HAE ,  TOMFORD WILLIAM W ,  YANNARIELLO-BROWN JUDITH I

IPC: A61K35/32 ,  A61K38/18 ,  A61L27/36 ,  A61L27/54

CPC classification number: A61K9/19 ,  A61K35/32 ,  A61K38/1825 ,  A61L27/3612 ,  A61L27/3654 ,  A61L27/54 ,  A61L2300/414 ,  A61L2300/602

Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ß8-ß9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ß8-ß9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.

Abstract translation: 包含冷冻研磨的软骨颗粒和外源生长因子的混合物如凝胶或糊剂用于修复软骨缺陷。 这样的混合物可以应用于包含松质骨的构建体以植入缺损部位。 合适的生长因子包括FGF-2的变体，特别是在FGF-2肽的β8-β9环的氨基酸111处包含天冬酰胺的单一氨基酸取代的变体。 这种FGF-2变体从软骨膏以恒定速率缓慢和连续释放。 在其他实施方案中，取代天冬氨酸的氨基酸是甘氨酸。 可以使用的其他变体包括在FGF-9肽的β8-β9环中具有截短的链和唯一的氨基酸取代的FGF-9变体，其在第144位的氨基酸为色氨酸或第143位的氨基酸为天冬酰胺。

公开(公告)号：WO2010009615A1

公开(公告)日：2010-01-28

申请号：PCT/CN2009/000816

申请日：2009-07-22

Applicant: GRANDHOPE BIOTECH CO., LTD. ,  XU, Guofeng ,  XU, Bin

Inventor： XU, Guofeng ,  XU, Bin

IPC: A61L27/36 ,  A61F2/28 ,  A61F2/30

CPC classification number: A61L27/3683 ,  A61F2/28 ,  A61F2/30756 ,  A61F2/3094 ,  A61F2002/30224 ,  A61F2230/0069 ,  A61L27/3612 ,  A61L27/3654 ,  A61L2430/06 ,  A61L2430/40

Abstract: A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking the animal material, removing antigens from the animal material, subjecting the animal material to an alkaline treatment, coupling into the animal material active substances which are capable of adhering growth factor and stem cell, and packing the animal material in a container that contains a sterilization solution.

Abstract translation: 根据包括从牛，羊或猪来源收集动物材料的步骤制备软骨假体，所述动物材料是软骨，使动物材料成形为软骨植入物提供期望的形状，从细胞中除去细胞 动物材料，交联动物材料，从动物材料中除去抗原，使动物材料进行碱处理，将能够粘附生长因子和干细胞的活性物质偶联到动物材料中，并将动物材料包装在 容器含有灭菌溶液。

公开(公告)号：WO2008092440A2

公开(公告)日：2008-08-07

申请号：PCT/DE2008000184

申请日：2008-02-01

Applicant: STIFTUNG CAESAR ,  THIE MICHAEL ,  DEGISTIRICI OEZER

Inventor： THIE MICHAEL ,  DEGISTIRICI OEZER

IPC: A61K35/12 ,  A61K35/32 ,  C12N5/06

CPC classification number: A61L27/3612 ,  A61K35/32 ,  A61L27/3608 ,  A61L27/3683 ,  A61L2430/40

Abstract: The invention relates to a therapeutic composition, a method for producing a therapeutic composition, and the use of a cell-free substance, especially a cell-free bone or cartilage matrix. The disclosed therapeutic composition comprises at least a cell-free substance obtained from stimulated stem cells and/or precursor cells. Immunogenic reactions during in vivo therapeutic use are prevented by the fact that the therapeutic composition is free from cells and contains no typically antigenic cell components. The disclosed composition can therefore be universally used for therapeutic purposes regardless of the origin of the stem cells and/or precursor cells and utilize the natural regenerative potency thereof in a highly efficient manner for replacing tissue, e.g. for a suitable bone and/or cartilage structure.

Abstract translation: 本发明涉及一种治疗组合物，用于治疗性组合物的制备以及使用了无细胞的物质的方法，特别是无细胞骨或软骨基质。 根据本发明的治疗组合物包括至少一个无细胞物质的已经从刺激干细胞和/或祖细胞出现了。 因为所述治疗组合物是无细胞的，并且通常含有无抗原的细胞成分，它不来在体内治疗应用的免疫原性反应。 本发明的组合物因此可以不管干细胞和/或祖细胞的来源的使用普遍用于治疗和使用他们的自然再生电力对组织替代，例如，一个合适的骨和/或软骨结构是高效的。

公开(公告)号：WO2007033509A1

公开(公告)日：2007-03-29

申请号：PCT/CH2006/000503

申请日：2006-09-18

Applicant: ZIMMER GMBH ,  STEINWACHS, Matthias, R. ,  BITTMANN, Peter

Inventor： STEINWACHS, Matthias, R. ,  BITTMANN, Peter

IPC: A61L27/36 ,  A61L27/38

CPC classification number: A61L27/3817 ,  A61L27/3612 ,  A61L27/3852

Abstract: For the repair of a cartilage defect in a human or animal patient, e.g. a full thickness articular cartilage defect, use is made of an implant (1) comprising an implant body (2) including a natural cartilage matrix and being coated with cells having a chondrogenic potential, preferably autologous cells. Preferably, the implant body consists of autologous cartilage tissue with viable chondrocytes integrated therein which cartilage tissue is produced by in vitro tissue culturing. Preferably, the cells for producing the cartilage tissue and for coating the implant body surfaces are the same. These cells are produced by in vitro cell proliferation starting from chondrocytes isolated from a cartilage biopsy. The chondrocytes which are de-differentiated during cell proliferation are re-differentiated during tissue culturing and are in particular suitable for producing and maintaining the cartilage matrix of the implant body. The cells adhering to the surface of the implant body are preferably also chondrocytes being de-differentiated by cell proliferation, but not re-differentiated, and are therefore particularly suitable for integrating the implant in the defect. Due to the cells adhering to the surface of the implant body, the implant is successfully integrated in the viable tissue surrounding the defect.

Abstract translation: 为了修复人或动物患者的软骨缺损，例如 全身关节软骨缺损，使用包括植入体（2）的植入物（1），其包括天然软骨基质并且涂覆有具有软骨形成潜能的细胞，优选自体细胞。 优选地，植入物主体由其中整合有活的软骨细胞的自体软骨组织组成，其中通过体外组织培养产生软骨组织。 优选地，用于产生软骨组织的细胞和用于涂覆植入物体表面的细胞是相同的。 这些细胞通过从软骨活检分离的软骨细胞开始的体外细胞增殖产生。 细胞增殖过程中去分化的软骨细胞在组织培养过程中被重新分化，特别适用于生产和维持植入体本体的软骨基质。 附着在植入体表面的细胞优选也是软骨细胞通过细胞增殖而被去分化，但不再分化，因此特别适用于将植入物整合到缺陷中。 由于细胞粘附到植入体的表面，植入物被成功地整合到围绕缺陷的活组织中。

公开(公告)号：WO2005110278A3

公开(公告)日：2006-08-10

申请号：PCT/US2005008798

申请日：2005-03-16

Applicant: MUSCULOSKELETAL TRANSPLANT ,  TRUNCALE KATHERINE ANN GOMES ,  GERTZMAN ARTHUR A

Inventor： TRUNCALE KATHERINE ANN GOMES ,  GERTZMAN ARTHUR A

IPC: A61F2/00 ,  A61B17/00 ,  A61F2/02 ,  A61F2/28 ,  A61F2/30 ,  A61F2/38 ,  A61L27/36 ,  A61L27/38 ,  A61L27/48 ,  A61L27/56 ,  A61L27/58

CPC classification number: A61F2/28 ,  A61B17/00491 ,  A61F2/30744 ,  A61F2/30756 ,  A61F2/3094 ,  A61F2/3859 ,  A61F2002/2817 ,  A61F2002/2867 ,  A61F2002/30062 ,  A61F2002/30224 ,  A61F2002/30225 ,  A61F2002/30759 ,  A61F2002/30764 ,  A61F2210/0004 ,  A61F2230/0069 ,  A61F2310/00365 ,  A61F2310/00383 ,  A61K35/28 ,  A61K35/32 ,  A61K38/18 ,  A61K38/28 ,  A61L27/20 ,  A61L27/24 ,  A61L27/3612 ,  A61L27/3654 ,  A61L27/3683 ,  A61L27/3817 ,  A61L27/3821 ,  A61L27/3834 ,  A61L27/3852 ,  A61L27/48 ,  A61L27/56 ,  A61L27/58 ,  A61L2430/06 ,  A61K2300/00 ,  C08L5/08

Abstract: The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5 x 10 5 to 2.5 x 10 7 .

Abstract translation: 本发明涉及一种无菌软骨缺损植入材料，其包含在生物可吸收载体中的尺寸范围为0.01mm至1.0mm的经研磨的冻干同种异体移植软骨片，其取自透明质酸钠及其衍生物，明胶，胶原，壳聚糖，藻酸盐 ，缓冲的PBS，葡聚糖或混合的聚合物，其加入量为2.5×10 5至2.5×10 7的量的同种异体移植软骨细胞。

公开(公告)号：WO2005113780A1

公开(公告)日：2005-12-01

申请号：PCT/US2005/016446

申请日：2005-05-12

Applicant: THE REGENTS OF THE UNIVERSITY ,  HEDRICK, Marc, H. ,  CARLSON, Grace ,  DRAGOO, Jason, Louis ,  BENHAIM, Prosper ,  LORENZ, Hermann, Peter ,  ZHU, Min ,  ZUK, Patrick ,  ASHJIAN, Peter

Inventor： HEDRICK, Marc, H. ,  CARLSON, Grace ,  DRAGOO, Jason, Louis ,  BENHAIM, Prosper ,  LORENZ, Hermann, Peter ,  ZHU, Min ,  ZUK, Patrick ,  ASHJIAN, Peter

IPC: C12N15/85

CPC classification number: A61L27/3612 ,  A61K35/12 ,  A61K48/00 ,  A61L27/225 ,  A61L27/3654 ,  A61L27/38 ,  C12N5/0068 ,  C12N5/0607 ,  C12N5/0647 ,  C12N5/0654 ,  C12N5/0655 ,  C12N5/0658 ,  C12N5/0667 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/01 ,  C12N2501/15 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2502/1305 ,  C12N2510/00 ,  C12N2533/90

Abstract: The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Abstract translation: 本发明单独提供脂肪来源的干细胞（ADSCs），脂肪来源的干细胞富含级分（ADSC-EF）和脂肪衍生的格子，并与本发明的ADSC组合。 一方面，本发明提供了基本上不含结缔组织干细胞的脂肪细胞和红细胞和克隆群体的ADSC。 ADSC可以单独使用或在生物相容性组合物内使用，以在体内和体外产生分化的组织和结构。 另外，可以扩增和培养ADSC以产生分子如激素，并提供条件培养基以支持其它细胞群的生长和扩增。 另一方面，本发明提供了一种基本上不含细胞的脂肪衍生的晶格，其包括来自脂肪组织的细胞外基质材料。 晶格可以用作底物，以促进细胞的生长和分化，无论是在体内还是在体外，成为成体组织或甚至成熟的组织或结构。